Ulcerative Colitis – Geographic Focus: China – Ulcerative Colitis – China In-Depth (China)
Ulcerative colitis (UC) is a chronic and progressive autoimmune disease that affects the gastrointestinal tract, specifically the colon and rectum. The principal goals of pharmacotherapy for UC are to induce remission during acute flares and to maintain remission over the long term. The severity of symptoms plays a defining role in drug selection, and certain therapies are better suited for treating acute flares and others for maintaining remission. Aminosalicylic acid (5-ASA) preparations are largely effective for mild to moderate disease. If treatment with 5-ASAs is ineffective, patients are prescribed corticosteroids. Use of biologics (e.g., infliximab, vedolizumab) and small molecules (e.g., JAK inhibitors) is primarily restricted to moderate to severe patients who do not respond to conventional treatments. This report provides a comprehensive analysis of the UC therapy market in China, including current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
Questions answered
- How large is China’s drug-treatable UC population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of UC in China?
- What are the key market access considerations for therapies in the UC pipeline in China? What sales / uptake could they secure in UC?
- What are the key drivers of and constraints in China’s UC therapy market, and how will the market evolve over the forecast period?
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
